Errol P. Prens

19.8k total citations · 6 hit papers
219 papers, 11.2k citations indexed

About

Errol P. Prens is a scholar working on Dermatology, Surgery and Immunology. According to data from OpenAlex, Errol P. Prens has authored 219 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Dermatology, 92 papers in Surgery and 67 papers in Immunology. Recurrent topics in Errol P. Prens's work include Hidradenitis Suppurativa and Treatments (96 papers), Colorectal and Anal Carcinomas (83 papers) and Psoriasis: Treatment and Pathogenesis (48 papers). Errol P. Prens is often cited by papers focused on Hidradenitis Suppurativa and Treatments (96 papers), Colorectal and Anal Carcinomas (83 papers) and Psoriasis: Treatment and Pathogenesis (48 papers). Errol P. Prens collaborates with scholars based in Netherlands, United States and Denmark. Errol P. Prens's co-authors include Hessel H. van der Zee, Jon D. Laman, Gregor B. E. Jemec, Jurr Boer, Inge E. Deckers, Leslie van der Fits, Edwin F. Florencia, Marius Kant, Christos C. Zouboulis and Erik Lubberts and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Annals of Internal Medicine.

In The Last Decade

Errol P. Prens

214 papers receiving 11.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

2009 1.6k citations Leslie van der Fits, Marius Kant et al. profile →
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

2015 731 citations Christos C. Zouboulis, Errol P. Prens et al. Journal of the European Academy of Dermatology and Venereology profile →
Hidradenitis suppurativa

2020 364 citations Gregor B. E. Jemec, Alexa B. Kimball et al. profile →
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β

2011 362 citations Hessel H. van der Zee, Jon D. Laman et al. British Journal of Dermatology profile →
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

2012 305 citations Alexa B. Kimball, Francisco A. Kerdel et al. Annals of Internal Medicine profile →
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

2024 71 citations Alexa B. Kimball, Gregor B. E. Jemec et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Errol P. Prens Netherlands	51	8.0k	4.9k	3.6k	2.5k	1.1k	219	11.2k
Michelle A. Lowes United States	49	6.3k 0.8×	1.3k 0.3×	8.8k 2.4×	1.0k 0.4×	1.7k 1.6×	113	12.4k
Nikhil Yawalkar Switzerland	43	2.8k 0.4×	672 0.1×	2.0k 0.6×	879 0.4×	376 0.4×	158	5.5k
Lasse R. Braathen Switzerland	42	2.6k 0.3×	528 0.1×	1.9k 0.5×	1.4k 0.6×	474 0.4×	150	6.0k
Brent S. McKenzie Australia	29	1.1k 0.1×	932 0.2×	9.6k 2.6×	1.2k 0.5×	2.0k 1.9×	45	12.5k
Erwin Schöpf Germany	44	3.6k 0.4×	579 0.1×	2.1k 0.6×	739 0.3×	690 0.6×	196	8.1k
Makoto Sugaya Japan	41	2.2k 0.3×	379 0.1×	2.8k 0.8×	929 0.4×	1.0k 0.9×	237	6.0k
Yan Zheng China	28	1.1k 0.1×	827 0.2×	4.7k 1.3×	698 0.3×	2.0k 1.9×	152	7.9k
Mona Ståhle Sweden	46	1.9k 0.2×	475 0.1×	4.0k 1.1×	531 0.2×	2.7k 2.5×	125	8.9k
Dagmar Simon Switzerland	44	2.4k 0.3×	1.7k 0.3×	2.2k 0.6×	318 0.1×	517 0.5×	162	6.9k
Tsen‐Fang Tsai Taiwan	43	3.9k 0.5×	283 0.1×	5.9k 1.6×	939 0.4×	675 0.6×	296	8.8k

Countries citing papers authored by Errol P. Prens

Since Specialization

Citations

This map shows the geographic impact of Errol P. Prens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Errol P. Prens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Errol P. Prens more than expected).

Fields of papers citing papers by Errol P. Prens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Errol P. Prens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Errol P. Prens. The network helps show where Errol P. Prens may publish in the future.

Co-authorship network of co-authors of Errol P. Prens

This figure shows the co-authorship network connecting the top 25 collaborators of Errol P. Prens. A scholar is included among the top collaborators of Errol P. Prens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Errol P. Prens. Errol P. Prens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ingram, John R, Angelo Valerio Marzano, Errol P. Prens, et al.. (2025). Hidradenitis suppurativa with and without draining tunnels: A real‐world study characterizing differences in treatment and disease burden. Journal of the European Academy of Dermatology and Venereology. 39(8). 1431–1441. 3 indexed citations

Zee, Hessel H. van der, et al.. (2025). Metformin in conjunction with doxycycline is not superior to doxycycline monotherapy for hidradenitis suppurativa; results of a phase III double-blinded randomized placebo- controlled trial. British Journal of Dermatology. 193(6). 1262–1264.

Wolkerstorfer, Albert, et al.. (2023). Needle-free electronically controlled jet injection with corticosteroids in recalcitrant keloid scars: a retrospective study and patient survey. Lasers in Medical Science. 38(1). 250–250. 6 indexed citations

Chen, Yanqing, Samuel E. DePrimo, Ernesto J. Muñoz‐Elías, et al.. (2023). Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. British Journal of Dermatology. 188(5). 601–609. 26 indexed citations

Zee, Hessel H. van der, et al.. (2023). Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting. Journal of the American Academy of Dermatology. 89(4). 677–684. 28 indexed citations

Tzellos, Thrasyvoulos, Kelsey R. van Straalen, Αthanassios Kyrgidis, et al.. (2022). Development and validation of IHS4‐55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology. 37(2). 395–401. 30 indexed citations

Dajnoki, Zsolt, Krisztián Gáspár, Pál Gergely, et al.. (2021). Primary alterations during the development of hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology. 36(3). 462–471. 27 indexed citations

Wolkerstorfer, Albert, et al.. (2021). Needle‐free jet injection‐induced small‐droplet aerosol formation during intralesional bleomycin therapy. Lasers in Surgery and Medicine. 54(4). 572–579. 5 indexed citations

Vossen, Allard R.J.V., et al.. (2021). Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs. 81(12). 1397–1410. 37 indexed citations

10.

Prens, Errol P., Aída Lugo‐Somolinos, Amy S. Paller, et al.. (2020). Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. American Journal of Clinical Dermatology. 21(4). 579–590. 16 indexed citations

11.

Straalen, Kelsey R. van, Ineke C. Janse, Christine B. Ardon, et al.. (2018). Correlation of the refined Hurley classification for hidradenitis suppurativa with patient‐reported quality of life and objective disease severity assessment. British Journal of Dermatology. 180(5). 1214–1220. 19 indexed citations

12.

Zouboulis, Christos C., Falk G. Bechara, Wayne Gulliver, et al.. (2018). Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. Journal of the European Academy of Dermatology and Venereology. 33(1). 19–31. 165 indexed citations

13.

Seelen, Marc A., et al.. (2018). Complement Activation in Inflammatory Skin Diseases. Frontiers in Immunology. 9. 639–639. 86 indexed citations

14.

Cohen, Arnon D., Jashin J. Wu, L. Puig, et al.. (2017). Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology. 177(6). 1495–1502. 33 indexed citations

15.

Vries, K. de, et al.. (2015). Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. British Journal of Dermatology. 174(3). 588–593. 43 indexed citations

16.

Rácz, Emöke & Errol P. Prens. (2015). Phototherapy and Photochemotherapy for Psoriasis. EUR Research Repository (Erasmus University Rotterdam). 30 indexed citations

17.

Kimball, Alexa B., Francisco A. Kerdel, David R. Adams, et al.. (2012). Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. Annals of Internal Medicine. 7 indexed citations

18.

Fits, Leslie van der, et al.. (2007). Polymorphisms in the Interferon Regulatory Factor-1 Promoter Are Not Associated with Psoriasis and Do Not Influence IFN- α -Induced Th1 Polarization. Journal of Interferon & Cytokine Research. 27(10). 841–846. 3 indexed citations

19.

Fits, Leslie van der, et al.. (2004). In Psoriasis Lesional Skin the Type I Interferon Signaling Pathway Is Activated, Whereas Interferon-α Sensitivity Is Unaltered. Journal of Investigative Dermatology. 122(1). 51–60. 103 indexed citations

20.

Prens, Errol P., et al.. (1989). Il-1 and il-6 in psoriasis. Journal of Investigative Dermatology. 93(4). 570–570. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact